<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02253030</url>
  </required_header>
  <id_info>
    <org_study_id>IRB#000010535</org_study_id>
    <nct_id>NCT02253030</nct_id>
  </id_info>
  <brief_title>OCT Angiography in Wet AMD</brief_title>
  <official_title>Optical Coherence Tomography Angiography in Neovascular Age-related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <brief_summary>
    <textblock>
      The primary goals of this study are to use optical coherence tomography (OCT) angiography
      (blood vessel mapping) to:

        1. diagnose the presence of new blood vessels in wet age-related macular degeneration (AMD)

        2. evaluate patients undergoing treatment for wet AMD

        3. determine if reduced flow to the choroid is a risk factor for developing wet AMD.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with new blood vessel growth detected using OCT angiography</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with reduced choroidal blood flow that develop wet AMD.</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Neovascular (Wet) Age-related Macular Degeneration (AMD)</condition>
  <arm_group>
    <arm_group_label>Newly-diagnosed, untreated wet AMD</arm_group_label>
    <description>This group will be adults newly diagnosed with wet AMD who have not undergone any treatment for the condition. Their data will be gathered only once, prior to treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Wet AMD undergoing &quot;as-needed&quot; treatment</arm_group_label>
    <description>This group will be adults undergoing treatment as-needed for wet AMD. They will be followed monthly over the course of 1 year.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-risk eyes</arm_group_label>
    <description>This group will be adults with wet AMD in one eye and findings of dry AMD in the other. The eye with dry AMD will be followed every 6 months for 3 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Wet AMD undergoing a &quot;treat and extend&quot; strategy</arm_group_label>
    <description>This group will be adults with wet AMD undergoing treatment under the &quot;treat and extend&quot; strategy. (The &quot;treat and extend&quot; strategy increases the intervals between treatments as long as the macula remains dry.) They will be followed over the course of 1 year with extra imaging before extending follow-up intervals.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Optical Coherence Tomography</intervention_name>
    <arm_group_label>Newly-diagnosed, untreated wet AMD</arm_group_label>
    <arm_group_label>Wet AMD undergoing &quot;as-needed&quot; treatment</arm_group_label>
    <arm_group_label>High-risk eyes</arm_group_label>
    <arm_group_label>Wet AMD undergoing a &quot;treat and extend&quot; strategy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Both female and male participants over the age of 50 are being studied.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria (Groups with wet AMD):

          -  Adults aged 50 and older with clinical findings of treatment-na√Øve (never treated)
             neovascular AMD with active new blood vessel growth confirmed by clinical testing will
             be considered

        Inclusion Criteria (Group with healthy eyes)

          -  No evidence of retinal disease

          -  Refractive error greater than +3.00 diopters or -7.00 diopters (glasses Rx)

          -  No recent eye surgery in the last 4 months

          -  No significant cataract to interfere with the quality of the imaging

        Exclusion Criteria (All Groups):

          -  Inability to give informed consent

          -  Significant kidney disease

          -  Blood pressure greater than 180/110

          -  Previous macular laser treatment

          -  Inability to maintain stable fixation during OCT imaging

          -  Visual acuity worse than 20/200
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Bailey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Omkar Thaware, B Optom, MSVS</last_name>
    <phone>503-494-7398</phone>
    <email>thaware@ohsu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Denny Romfh, OD</last_name>
    <phone>503-494-4351</phone>
    <email>romfhd@ohsu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Casey Eye Institute, Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Omkar Thaware, B Optom, MSVS</last_name>
      <phone>503-494-7398</phone>
      <email>thaware@ohsu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Denny Romfh, OD</last_name>
      <phone>503-494-4351</phone>
      <email>romfhd@ohsu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Christina Flaxel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Hwang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Klein, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Phoebe Lin, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andreas Lauer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kavita Bhavsar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Campbell, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yali Jia, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ou Tan, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2014</study_first_submitted>
  <study_first_submitted_qc>September 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2014</study_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>David Huang</investigator_full_name>
    <investigator_title>Steven Bailey, MD, Assistant Professor of Ophthalmology</investigator_title>
  </responsible_party>
  <keyword>AMD</keyword>
  <keyword>OCT</keyword>
  <keyword>Angiography</keyword>
  <keyword>Macular degeneration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

